MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy
NCT ID: NCT00963300
Last Updated: 2018-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2009-09-30
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying how well MRI works in assessing hypoxia in patients with localized prostate cancer undergoing stereotactic body radiation therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterize Tumor Hypoxia by Magnetic Resonance Imaging
NCT03987568
The Potential Use of BOLD MRI as a Noninvasive Measure of Tumor Hypoxia in Prostate Cancer
NCT00242073
Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma
NCT00230386
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
NCT06391034
Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer
NCT02163317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To characterize the status of global hypoxia within the prostate before stereotactic body radiotherapy (SBRT) as assessed by blood-oxygen-level-dependent and tissue-oxygen-level-dependent MRI.
* To characterize tumor vasculature and metabolism within the prostate before SBRT as assessed by dynamic contrast-enhanced MRI and magnetic resonance spectroscopic imaging, respectively.
* Correlate prostate and normal tissue hypoxia before SBRT with clinical outcomes (toxicity and biochemical \[PSA\] control) after SBRT.
OUTLINE: Within 1-3 weeks before beginning stereotactic body radiotherapy, patients undergo T2-weighted anatomic MRI, magnetic resonance spectroscopic imaging, blood-oxygen-level-dependent and tissue-oxygen-level-dependent MRI, and dynamic contrast-enhanced MRI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood-oxygen-level-dependent functional magnetic resonance imaging
dynamic contrast-enhanced magnetic resonance imaging
magnetic resonance spectroscopic imaging
tissue-oxygen-level-dependent functional magnetic resonance imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Biopsy proven adenocarcinoma of the prostate
* Localized disease
* Scheduled to undergo treatment with stereotactic body radiotherapy (SBRT) on a phase II clinical trial
* Has not yet started SBRT
PATIENT CHARACTERISTICS:
* Serum creatinine ≤ 1.2 mg/dL
* No claustrophobia
* No other contraindication to MRI (e.g., implanted pacemaker device)
* No known allergy to MRI contrast
PRIOR CONCURRENT THERAPY:
* No prior treatment for prostate cancer (e.g., hormonal therapy or chemotherapy)
18 Years
120 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas Southwestern Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert D. Timmerman, MD
Role: PRINCIPAL_INVESTIGATOR
Simmons Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000652306
Identifier Type: REGISTRY
Identifier Source: secondary_id
SCCC-062009-014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.